CTI BioPharma Corp. [NASDAQ: CTIC] traded at a high on 07/05/22, posting a 2.80 gain after which it closed the day’ session at $6.25. The company report on June 14, 2022 that CTI BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).
China Can't Stop US$0.25 Stock from Mining Ultra-Rare Metal
Here's one little-known company — trading undiscovered below 25-cents per share — that's advancing one of the largest and highest quality REE deposits in all of North America... and the Chinese can't do a damn thing about it! It's early stage... and that's excellent news for individual investors like you who have the foresight to act decisively on an emerging megatrend that's already being measured in the Tens of $Billions.
Simply click here and the name & trading symbol are yours.
CTI BioPharma Corp. (NASDAQ: CTIC) today announced that an authorized subcommittee of the Compensation Committee of its Board of Directors granted an equity award to a new employee as an equity inducement award outside of the Company’s Amended and Restated 2017 Equity Incentive Plan (but under the terms of the Amended and Restated 2017 Equity Incentive Plan) and material to the employee’s acceptance of employment with the company. The equity award was approved on June 13, 2022, in accordance with Nasdaq Listing Rule 5635(c)(4).
The employee received options to purchase 40,000 shares of CTI BioPharma common stock. The options will be issued upon the employee’s grant date (the “Grant Date”), and all stock options included within the equity inducement award will have an exercise price equal to the closing price of CTI BioPharma common stock on the Grant Date. One-fourth of the options will vest on each anniversary of the employee’s Grant Date, subject to the employee’s continued employment with CTI BioPharma on such vesting dates. The options have a ten-year term.
The results of the trading session contributed to over 4345423 shares changing hands. Over the past one week, the price volatility of CTI BioPharma Corp. stands at 8.29% while the volatility over the past one month is 9.24%.
The market cap for CTIC stock reached $668.69 million, with 99.83 million shares outstanding and 74.15 million shares in the current float. Compared to the average trading volume of 4.48M shares, CTIC reached a trading volume of 4345423 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about CTI BioPharma Corp. [CTIC]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for CTIC shares is $9.58 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on CTIC stock is a recommendation set at 1.70. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
BTIG Research have made an estimate for CTI BioPharma Corp. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on August 09, 2021. While these analysts kept the previous recommendation, Stifel raised their target price to Buy. The new note on the price target was released on May 06, 2021, representing the official price target for CTI BioPharma Corp. stock. Previously, the target price had yet another raise to $3, while JMP Securities analysts kept a Mkt Outperform rating on CTIC stock.
The Average True Range (ATR) for CTI BioPharma Corp. is set at 0.48, with the Price to Sales ratio for CTIC stock in the period of the last 12 months amounting to 290.73.
How has CTIC stock performed recently?
CTI BioPharma Corp. [CTIC] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 10.82. With this latest performance, CTIC shares gained by 2.80% in over the last four-week period, additionally plugging by 152.02% over the last 6 months – not to mention a rise of 140.38% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for CTIC stock in for the last two-week period is set at 59.98, with the RSI for the last a single of trading hit 63.24, and the three-weeks RSI is set at 58.53 for CTI BioPharma Corp. [CTIC]. The present Moving Average for the last 50 days of trading for this stock 5.29, while it was recorded at 5.86 for the last single week of trading, and 3.51 for the last 200 days.
CTI BioPharma Corp. [CTIC]: Deeper insight into the fundamentals
Return on Equity for this stock declined to -447.11, with Return on Assets sitting at -149.85.
CTI BioPharma Corp.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.00 and a Current Ratio set at 1.00.
Insider trade positions for CTI BioPharma Corp. [CTIC]
There are presently around $363 million, or 56.90% of CTIC stock, in the hands of institutional investors. The top three institutional holders of CTIC stocks are: BVF INC/IL with ownership of 8,929,690, which is approximately 0% of the company’s market cap and around 0.23% of the total institutional ownership; NEA MANAGEMENT COMPANY, LLC, holding 7,140,450 shares of the stock with an approximate value of $43.41 million in CTIC stocks shares; and LION POINT CAPITAL, LP, currently with $33.38 million in CTIC stock with ownership of nearly 348.641% of the company’s market capitalization.
Positions in CTI BioPharma Corp. stocks held by institutional investors increased at the end of August and at the time of the August reporting period, where 55 institutional holders increased their position in CTI BioPharma Corp. [NASDAQ:CTIC] by around 21,997,711 shares. Additionally, 22 investors decreased positions by around 10,109,975 shares, while 17 investors held positions by with 27,521,010 shares. The mentioned changes placed institutional holdings at 59,628,696 shares, according to the latest SEC report filing. CTIC stock had 31 new institutional investments in for a total of 6,875,635 shares, while 4 institutional investors sold positions of 2,239,345 shares during the same period.